Yong Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yong Cui has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Chunquan Liu
Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
6 shared publicationsPeng Song
4 shared publications- Chunquan Liu
Department of Thoracic Surgery, Beijing Friendship Hospital Capital Medical University Beijing China
3 shared publications - Dong Chang
Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
3 shared publications Ying He
Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
3 shared publicationsDong Chang
Department of Thoracic Surgery Beijing Friendship Hospital, Capital Medical University Beijing China
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Cell Death & Disease
Spatial multi-omics reveals that CXCL10 enhances the response to nICT in surgically resectable esophageal squamous cell carcinoma
Neoadjuvant immune-chemotherapy (nICT) has transformed the treatment strategy for esophageal squamous cell carcinoma (ESCC), yet the molecular mechanisms underlying treatment response remain incompletely understood. To investigate these mechanisms, we jointly analyzed matched ESCC specimens obtained before and after neoadjuvant therapy using single-cell transcriptomic profiling, spatial transcriptomics, and spatial metabolomic imaging. This multilayered, same-sample framework revealed extensive remodeling of the tumor microenvironment, including enhanced immune activation and marked changes in the spatial organization of major cellular populations. Notably, CXCL10 increased the intratumoral proportion of CD8⁺ T cells, promoted their cytotoxic activation, and enhanced T-cell–mediated tumor elimination both in vitro and in vivo. Genetic silencing or pharmacological inhibition of CXCR3 attenuated these effects and diminished the therapeutic benefit of anti-PD1 treatment, supporting a functional role for the CXCL10–CXCR3 axis in modulating immunotherapy efficacy. Spatial metabolomics further revealed pronounced remodeling of ornithine metabolism in malignant regions, characterized by suppression of the urea cycle, potential involvement of a glutamate/proline-linked ornithine pathway, and enhanced polyamine synthesis. An ornithine metabolism-related gene signature was strongly associated with poor prognosis in the TCGA-ESCC cohort, while pharmacological inhibition of ornithine decarboxylase enhanced the antitumor efficacy of anti-PD1 therapy in vivo. Together, these findings provide a spatial multi-omics atlas of ESCC following nICT and identify the CXCL10–CXCR3 axis and ornithine-centered metabolic remodeling as potentially actionable immune and metabolic features associated with treatment response.
- 15 October 2026
- Published by Springer Nature in Cell Death & Disease
Open AccessSpatial multi-omics reveals that CXCL10 enhances the response to nICT in surgically resectable esophageal squamous cell carcinoma
Neoadjuvant immune-chemotherapy (nICT) has transformed the treatment strategy for esophageal squamous cell carcinoma (ESCC), yet the molecular mechanisms underlying treatment response remain incompletely understood. To investigate these mechanisms, we jointly analyzed matched ESCC specimens obtained before and after neoadjuvant therapy using single-cell transcriptomic profiling, spatial transcriptomics, and spatial metabolomic imaging. This multilayered, same-sample framework revealed extensive remodeling of the tumor microenvironment, including enhanced immune activation and marked changes in the spatial organization of major cellular populations. Notably, CXCL10 increased the intratumoral proportion of CD8⁺ T cells, promoted their cytotoxic activation, and enhanced T-cell–mediated tumor elimination both in vitro and in vivo. Genetic silencing or pharmacological inhibition of CXCR3 attenuated these effects and diminished the therapeutic benefit of anti-PD1 treatment, supporting a functional role for the CXCL10–CXCR3 axis in modulating immunotherapy efficacy. Spatial metabolomics further revealed pronounced remodeling of ornithine metabolism in malignant regions, characterized by suppression of the urea cycle, potential involvement of a glutamate/proline-linked ornithine pathway, and enhanced polyamine synthesis. An ornithine metabolism-related gene signature was strongly associated with poor prognosis in the TCGA-ESCC cohort, while pharmacological inhibition of ornithine decarboxylase enhanced the antitumor efficacy of anti-PD1 therapy in vivo. Together, these findings provide a spatial multi-omics atlas of ESCC following nICT and identify the CXCL10–CXCR3 axis and ornithine-centered metabolic remodeling as potentially actionable immune and metabolic features associated with treatment response.
- Open Access
- 1 August 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (8) , 885
Noninvasive prediction of ALK fusion status in non-small cell lung cancer by a machine learning model combining CT images and clinical information
Background: As the primary contributor to global cancer mortality, lung cancer requires precise anaplastic lymphoma kinase (ALK) genotyping to implement personalized targeted treatment for non-small cell lung cancer (NSCLC) patients. Invasive biopsy-based ALK detection is clinically limited by sampling deviation, procedural complications, and insufficient tumor specimens. The objective of this study was to develop and validate a machine learning model that integrates computed tomography (CT) radiomics features with clinicopathological data to non-invasively predict ALK fusion status in patients with NSCLC. Methods: This retrospective multi-center study enrolled 722 NSCLC patients (291 ALK-positive, 431 ALK-negative). From segmented tumor regions, 2,264 radiomics features were derived. After feature selection using the least absolute shrinkage and selection operator (LASSO) regression, three predictive models were constructed and compared: a clinical & region of interest (ROI) model, a radiomics model, and a combined model integrating both feature types. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity in training, test, and validation cohorts. Results: The final models included 14, 67, and 53 features in the clinical & ROI model, radiomics model, and combined model, respectively. The combined model demonstrated superior predictive performance, achieving an AUC of 0.997 in the training cohort, 0.988 in the test cohort, and 0.973 in the validation cohort. It significantly outperformed the clinical & ROI model (AUC: 0.997 vs. 0.923 in the training cohort, P vs. 0.995 in the training cohort, P=0.18), though not statistically significant. Conclusions: A machine learning model combining CT radiomics and clinical data exhibited robust performance in predicting ALK fusion status in NSCLC patients. This non-invasive approach shows significant potential as a clinical tool for pre-therapeutic selection of patients who may benefit from ALK-targeted therapies.
- 1 August 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (8) , 885
Open AccessNoninvasive prediction of ALK fusion status in non-small cell lung cancer by a machine learning model combining CT images and clinical information
Background: As the primary contributor to global cancer mortality, lung cancer requires precise anaplastic lymphoma kinase (ALK) genotyping to implement personalized targeted treatment for non-small cell lung cancer (NSCLC) patients. Invasive biopsy-based ALK detection is clinically limited by sampling deviation, procedural complications, and insufficient tumor specimens. The objective of this study was to develop and validate a machine learning model that integrates computed tomography (CT) radiomics features with clinicopathological data to non-invasively predict ALK fusion status in patients with NSCLC. Methods: This retrospective multi-center study enrolled 722 NSCLC patients (291 ALK-positive, 431 ALK-negative). From segmented tumor regions, 2,264 radiomics features were derived. After feature selection using the least absolute shrinkage and selection operator (LASSO) regression, three predictive models were constructed and compared: a clinical & region of interest (ROI) model, a radiomics model, and a combined model integrating both feature types. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity in training, test, and validation cohorts. Results: The final models included 14, 67, and 53 features in the clinical & ROI model, radiomics model, and combined model, respectively. The combined model demonstrated superior predictive performance, achieving an AUC of 0.997 in the training cohort, 0.988 in the test cohort, and 0.973 in the validation cohort. It significantly outperformed the clinical & ROI model (AUC: 0.997 vs. 0.923 in the training cohort, P vs. 0.995 in the training cohort, P=0.18), though not statistically significant. Conclusions: A machine learning model combining CT radiomics and clinical data exhibited robust performance in predicting ALK fusion status in NSCLC patients. This non-invasive approach shows significant potential as a clinical tool for pre-therapeutic selection of patients who may benefit from ALK-targeted therapies.
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (6) , 181
Consolidation thoracic radiotherapy following quadruple induction with benmelstobart, anlotinib, and chemotherapy for extensive-stage small cell lung cancer: rationale and protocol of a phase II study
Extensive-stage small cell lung cancer (ES-SCLC) remains a highly aggressive malignancy with limited survival outcomes. While first-line immune checkpoint inhibitors combined with platinum-based chemotherapy have improved survival, the benefit is modest. Emerging evidence supports the integration of anti-angiogenic therapy and thoracic radiotherapy (TRT) to enhance systemic and local control. However, a comprehensive multimodal regimen combining chemotherapy, immunotherapy, anti-angiogenic therapy, and TRT has not been systematically evaluated. This study aims to assess the safety, feasibility, and preliminary efficacy of a multimodal treatment strategy involving induction with benmelstobart (an anti-programmed death-ligand 1 [PD-L1] antibody), platinum-etoposide chemotherapy, and anlotinib, followed by consolidation with benmelstobart, anlotinib, and sequential TRT in patients with untreated ES-SCLC.
- 1 June 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (6) , 181
Open AccessConsolidation thoracic radiotherapy following quadruple induction with benmelstobart, anlotinib, and chemotherapy for extensive-stage small cell lung cancer: rationale and protocol of a phase II study
Extensive-stage small cell lung cancer (ES-SCLC) remains a highly aggressive malignancy with limited survival outcomes. While first-line immune checkpoint inhibitors combined with platinum-based chemotherapy have improved survival, the benefit is modest. Emerging evidence supports the integration of anti-angiogenic therapy and thoracic radiotherapy (TRT) to enhance systemic and local control. However, a comprehensive multimodal regimen combining chemotherapy, immunotherapy, anti-angiogenic therapy, and TRT has not been systematically evaluated. This study aims to assess the safety, feasibility, and preliminary efficacy of a multimodal treatment strategy involving induction with benmelstobart (an anti-programmed death-ligand 1 [PD-L1] antibody), platinum-etoposide chemotherapy, and anlotinib, followed by consolidation with benmelstobart, anlotinib, and sequential TRT in patients with untreated ES-SCLC.
- Open Access
- 1 August 2025
- Published by Wiley in Thoracic Cancer
- Vol. 16 (15) , e70136
Microwave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB–IIIB Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study
Background: Chemotherapy combined with immunotherapy has emerged as a pivotal neoadjuvant strategy for resectable locally advanced non‐small cell lung cancer (NSCLC). However, several problems urge to be resolved, including suboptimal pathologic complete response(pCR)/major pathologic response (MPR). Microwave ablation (MWA) exerts direct tumoricidal effects through thermal coagulation while releasing tumor‐associated antigens to remodel the local immune microenvironment. In patients with advanced NSCLC, MWA combined with chemotherapy or immunotherapy has shown prolonged overall survival (OS).Methods: This study investigated the neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy for optimizing neoadjuvant treatment strategies of stage IIB–IIIB NSCLC. We evaluated the pCR, MPR, R0 resection rate, and incidence of grade ≥ 3 adverse events in patients following surgical resection, aiming to improve surgical outcomes and survival.Results: This study confirmed the safety and feasibility of a neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy in patients with NSCLC. The study was a single‐center retrospective analysis (n = 8), demonstrating a pCR rate of 50%, an MPR rate of 62.5%, an R0 resection rate of 100%, with no increase in grade ≥ 3 adverse events.Conclusions: In this retrospective analysis, the neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy preliminarily demonstrates safety and feasibility in resectable stage IIB–IIIB NSCLC, while showing potential to improve pCR and MPR rates. Furthermore, the integration of MWA may propose a novel treatment approach for optimizing neoadjuvant therapy. Prospective multicenter clinical trials are required to further validate the safety and feasibility, as well as its impact on long‐term survival benefits.
- 1 August 2025
- Published by Wiley in Thoracic Cancer
- Vol. 16 (15) , e70136
Open AccessMicrowave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB–IIIB Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study
Background: Chemotherapy combined with immunotherapy has emerged as a pivotal neoadjuvant strategy for resectable locally advanced non‐small cell lung cancer (NSCLC). However, several problems urge to be resolved, including suboptimal pathologic complete response(pCR)/major pathologic response (MPR). Microwave ablation (MWA) exerts direct tumoricidal effects through thermal coagulation while releasing tumor‐associated antigens to remodel the local immune microenvironment. In patients with advanced NSCLC, MWA combined with chemotherapy or immunotherapy has shown prolonged overall survival (OS).Methods: This study investigated the neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy for optimizing neoadjuvant treatment strategies of stage IIB–IIIB NSCLC. We evaluated the pCR, MPR, R0 resection rate, and incidence of grade ≥ 3 adverse events in patients following surgical resection, aiming to improve surgical outcomes and survival.Results: This study confirmed the safety and feasibility of a neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy in patients with NSCLC. The study was a single‐center retrospective analysis (n = 8), demonstrating a pCR rate of 50%, an MPR rate of 62.5%, an R0 resection rate of 100%, with no increase in grade ≥ 3 adverse events.Conclusions: In this retrospective analysis, the neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy preliminarily demonstrates safety and feasibility in resectable stage IIB–IIIB NSCLC, while showing potential to improve pCR and MPR rates. Furthermore, the integration of MWA may propose a novel treatment approach for optimizing neoadjuvant therapy. Prospective multicenter clinical trials are required to further validate the safety and feasibility, as well as its impact on long‐term survival benefits.
- Open Access
- 31 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes
Background: Inflammatory indexes are increasingly being considered to predict treatment response in tumors. This study aimed to investigate the efficacy of serum inflammatory indexes in predicting pathological response in patients with esophageal squamous cell carcinoma (ESCC) receiving anti-PD-1 neoadjuvant immunochemotherapy (NICT). Methods: We retrospectively collected clinical and laboratory data from 116 ESCC patients who received NICT. We set three outcome variables: pathologic complete response (PCR), good response (GR), and response (R). We assessed between-group differences in inflammation indexes and their diagnostic efficacy. Independent diagnostic markers were filtered using least absolute shrinkage and selection operator (LASSO) logistic regression and multivariable analysis, and the corresponding nomograms for PCR and GR were constructed, respectively. Receiver operating characteristic curves (ROC) and calibration curves assessed the efficiency and accuracy of the models. Decision curve analysis (DCA) and clinical impact curves (CIC) evaluated the clinical value. Moreover, we internally validated the predictive model with a random sample of 30% of patients. Results: The prognostic nutritional index (PNI) predicted a cutoff value of 53.585 for PCR with an area under curve (AUC) value of 0.720, a cutoff value of 47.85 for GR with an AUC of 0.723, a cutoff value of 47.85 for R with an AUC of 0.629. Smoking and PNI were independent predictors of PCR, platelet-to-lymphocyte ratio (PLR) and PNI were independent predictors of GR, and PNI was an independent predictor of R. We built PNI-based nomograms to predict PCR and GR with AUC values of 0.795 and 0.763 for the training cohort and 0.907 and 0.757 for the validation cohort, respectively. The predicted and actual results of the calibration curves for both the training and validation groups showed good agreement, with Brier scores below 0.25. Conclusion: High PNI value is a shared independent predictor of achieving PCR, GR, and R in ESCC patients receiving anti-PD1 NICT. PNI-based diagnostic models can be used as a practical tool to identify ideal patients for personalized clinical decisions.
- 31 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessPredicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes
Background: Inflammatory indexes are increasingly being considered to predict treatment response in tumors. This study aimed to investigate the efficacy of serum inflammatory indexes in predicting pathological response in patients with esophageal squamous cell carcinoma (ESCC) receiving anti-PD-1 neoadjuvant immunochemotherapy (NICT). Methods: We retrospectively collected clinical and laboratory data from 116 ESCC patients who received NICT. We set three outcome variables: pathologic complete response (PCR), good response (GR), and response (R). We assessed between-group differences in inflammation indexes and their diagnostic efficacy. Independent diagnostic markers were filtered using least absolute shrinkage and selection operator (LASSO) logistic regression and multivariable analysis, and the corresponding nomograms for PCR and GR were constructed, respectively. Receiver operating characteristic curves (ROC) and calibration curves assessed the efficiency and accuracy of the models. Decision curve analysis (DCA) and clinical impact curves (CIC) evaluated the clinical value. Moreover, we internally validated the predictive model with a random sample of 30% of patients. Results: The prognostic nutritional index (PNI) predicted a cutoff value of 53.585 for PCR with an area under curve (AUC) value of 0.720, a cutoff value of 47.85 for GR with an AUC of 0.723, a cutoff value of 47.85 for R with an AUC of 0.629. Smoking and PNI were independent predictors of PCR, platelet-to-lymphocyte ratio (PLR) and PNI were independent predictors of GR, and PNI was an independent predictor of R. We built PNI-based nomograms to predict PCR and GR with AUC values of 0.795 and 0.763 for the training cohort and 0.907 and 0.757 for the validation cohort, respectively. The predicted and actual results of the calibration curves for both the training and validation groups showed good agreement, with Brier scores below 0.25. Conclusion: High PNI value is a shared independent predictor of achieving PCR, GR, and R in ESCC patients receiving anti-PD1 NICT. PNI-based diagnostic models can be used as a practical tool to identify ideal patients for personalized clinical decisions.
- Open Access
- 18 November 2024
- Published by Wiley in Thoracic Cancer
- Vol. 16 (1)
Optical sensor for fast and accurate lung cancer detection with tissue autofluorescence and diffuse reflectance spectroscopy
Background: Cancer is a severe threat to human health, and surgery is a major method of cancer treatment. This study aimed to develop an optical sensor for fast cancer tissue.Methods: The tissue autofluorescence spectrum and diffuse reflectance spectrum were obtained by using a laboratory‐developed optical sensor system. A total of 151 lung tissue samples were used in this ex vivo study.Results: Experimental results demonstrate that tissue autofluorescence spectroscopy with a 365‐nm excitation has better performance than diffuse reflectance spectroscopy, and 63 of 64 test samples (98.4% accuracy) were correctly classified with tissue autofluorescence spectroscopy and our developed data analysis method.Conclusions: Our promising ex vivo study results show that the developed optical sensor system has great promise for future clinical translation for intraoperative lung cancer detection and other applications.
- 18 November 2024
- Published by Wiley in Thoracic Cancer
- Vol. 16 (1)
Open AccessOptical sensor for fast and accurate lung cancer detection with tissue autofluorescence and diffuse reflectance spectroscopy
Background: Cancer is a severe threat to human health, and surgery is a major method of cancer treatment. This study aimed to develop an optical sensor for fast cancer tissue.Methods: The tissue autofluorescence spectrum and diffuse reflectance spectrum were obtained by using a laboratory‐developed optical sensor system. A total of 151 lung tissue samples were used in this ex vivo study.Results: Experimental results demonstrate that tissue autofluorescence spectroscopy with a 365‐nm excitation has better performance than diffuse reflectance spectroscopy, and 63 of 64 test samples (98.4% accuracy) were correctly classified with tissue autofluorescence spectroscopy and our developed data analysis method.Conclusions: Our promising ex vivo study results show that the developed optical sensor system has great promise for future clinical translation for intraoperative lung cancer detection and other applications.
- Open Access
- 20 May 2024
- Vol. 27 (5) , 383-390
[Progress and Discussion of Perioperative Targeted Therapy in Patients with EGFR-mutated Resectable Non-small Cell Lung Cancer].
Lung cancer is still the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, accounting for about 80%. Approximately 30% of all patients with NSCLC have resectable early and middle stage disease at the time of diagnosis. Recently, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have made a major breakthrough in the adjuvant targeted therapy of EGFR-mutated resectable NSCLC, and are recommended by the guidelines for clinical use. In this review, we summarize the clinical research progress of perioperative adjuvant targeted therapy for EGFR-mutated resectable NSCLC, and discuss the key issues in the clinical researches. .
- 20 May 2024
- Vol. 27 (5) , 383-390
Open Access[Progress and Discussion of Perioperative Targeted Therapy in Patients with EGFR-mutated Resectable Non-small Cell Lung Cancer].
Lung cancer is still the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, accounting for about 80%. Approximately 30% of all patients with NSCLC have resectable early and middle stage disease at the time of diagnosis. Recently, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have made a major breakthrough in the adjuvant targeted therapy of EGFR-mutated resectable NSCLC, and are recommended by the guidelines for clinical use. In this review, we summarize the clinical research progress of perioperative adjuvant targeted therapy for EGFR-mutated resectable NSCLC, and discuss the key issues in the clinical researches. .
- 29 April 2024
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 48 (1) , 6-17
Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
With the development of immune checkpoints inhibitors (ICIs), immunotherapy has recently taken center stage in cancer treatment. Dendritic cells exert complicated and important functions in antitumor immunity. This study aims to construct a novel dendritic cell marker gene signature (DCMGS) to predict the prognosis and immunotherapy response of lung adenocarcinoma (LUAD). DC marker genes in LUAD were identified by analysis of single-cell RNA sequencing data. 6 genes (G0S2, KLF4, ALDH2, IER3, TXN, CD69) were screened as the most prognosis-related genes for constructing DCMGS on a training cohort from TCGA data set. Patients were divided into high-risk and low-risk groups by DCMGS risk score based on overall survival time. Then, the predictive ability of the risk model was validated in 6 independent cohorts. DCMGS was verified to be an independent prognostic factor in multivariate analysis. Furthermore, we performed pathway enrichment analysis to explore possible biological mechanisms of the powerful predictive ability of DCMGS, and immune cell infiltration landscape and inflammatory activities were exhibited to reflect the immune profile. Notably, we bridged DCMGS with expression of immune checkpoints and TCR/BCR repertoire diversity that can inflect immunotherapy response. Finally, the predictive ability of DCMGS in immunotherapy response was also validated by 2 cohorts that had received immunotherapy. As a result, the patients with lower DCMGS risk scores showed a better prognosis and immunotherapy response. In conclusion, DCMGS was suggested to be a promising prognostic indicator for LUAD and a desirable predictor for immunotherapy response.
- 29 April 2024
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 48 (1) , 6-17
Comprehensive Analysis of a Dendritic Cell Marker Genes Signature to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma
With the development of immune checkpoints inhibitors (ICIs), immunotherapy has recently taken center stage in cancer treatment. Dendritic cells exert complicated and important functions in antitumor immunity. This study aims to construct a novel dendritic cell marker gene signature (DCMGS) to predict the prognosis and immunotherapy response of lung adenocarcinoma (LUAD). DC marker genes in LUAD were identified by analysis of single-cell RNA sequencing data. 6 genes (G0S2, KLF4, ALDH2, IER3, TXN, CD69) were screened as the most prognosis-related genes for constructing DCMGS on a training cohort from TCGA data set. Patients were divided into high-risk and low-risk groups by DCMGS risk score based on overall survival time. Then, the predictive ability of the risk model was validated in 6 independent cohorts. DCMGS was verified to be an independent prognostic factor in multivariate analysis. Furthermore, we performed pathway enrichment analysis to explore possible biological mechanisms of the powerful predictive ability of DCMGS, and immune cell infiltration landscape and inflammatory activities were exhibited to reflect the immune profile. Notably, we bridged DCMGS with expression of immune checkpoints and TCR/BCR repertoire diversity that can inflect immunotherapy response. Finally, the predictive ability of DCMGS in immunotherapy response was also validated by 2 cohorts that had received immunotherapy. As a result, the patients with lower DCMGS risk scores showed a better prognosis and immunotherapy response. In conclusion, DCMGS was suggested to be a promising prognostic indicator for LUAD and a desirable predictor for immunotherapy response.
- Open Access
- 12 January 2024
- Published by Wiley in Thoracic Cancer
- Vol. 15 (6) , 486-495
Causal effects of gut microbiota in the development of lung cancer and its histological subtypes: A Mendelian randomization study
Background: Numerous studies have characterized the gut microbiome (GM) in lung cancer (LC). Yet, the causality between GM and LC and its subtypes remain uncharacterized.Methods: Two‐sample Mendelian randomization (MR) was designed to investigate the causal relationship between the GM and LC and its subtypes, using publicly available summary data of genome‐wide association studies. The researchers ran two groups of MR analyses, including the genome‐wide statistical significance threshold (5 × 10−8) and the locus‐wide significance level (1 × 10−5).Results: Using MR analysis, we ascertained 42 groups of GM that are intimately linked to LC and its subtypes at the locus‐wide significance level. Of the 42 groups, 12 were in LC, nine in non‐small cell lung cancer (NSCLC), six in small cell lung cancer (SCLC), two in lung adenocarcinomas, and 13 in lung squamous carcinomas. After false discovery rate correction, we still found a remarkable causal interaction between the Eubacterium ruminantium group and SCLC. Moreover, five groups of GM closely linked to LC and its subtypes were recognised at the genome‐wide statistical significance threshold. This finding included one group each in LC, NSCLC and SCLC, two groups in lung adenocarcinoma and none in lung squamous carcinoma. None of the foregoing findings were heterogeneous or horizontal pleiotropy. Reverse MR revealed that genetic susceptibility to LC and its subtypes caused significant changes in three groups of GM.Conclusion: Our findings substantiate the causality between GM and LC and its subtypes. This study offers fresh insights into the function of GM in mediating the progression of LC.
- 12 January 2024
- Published by Wiley in Thoracic Cancer
- Vol. 15 (6) , 486-495
Open AccessCausal effects of gut microbiota in the development of lung cancer and its histological subtypes: A Mendelian randomization study
Background: Numerous studies have characterized the gut microbiome (GM) in lung cancer (LC). Yet, the causality between GM and LC and its subtypes remain uncharacterized.Methods: Two‐sample Mendelian randomization (MR) was designed to investigate the causal relationship between the GM and LC and its subtypes, using publicly available summary data of genome‐wide association studies. The researchers ran two groups of MR analyses, including the genome‐wide statistical significance threshold (5 × 10−8) and the locus‐wide significance level (1 × 10−5).Results: Using MR analysis, we ascertained 42 groups of GM that are intimately linked to LC and its subtypes at the locus‐wide significance level. Of the 42 groups, 12 were in LC, nine in non‐small cell lung cancer (NSCLC), six in small cell lung cancer (SCLC), two in lung adenocarcinomas, and 13 in lung squamous carcinomas. After false discovery rate correction, we still found a remarkable causal interaction between the Eubacterium ruminantium group and SCLC. Moreover, five groups of GM closely linked to LC and its subtypes were recognised at the genome‐wide statistical significance threshold. This finding included one group each in LC, NSCLC and SCLC, two groups in lung adenocarcinoma and none in lung squamous carcinoma. None of the foregoing findings were heterogeneous or horizontal pleiotropy. Reverse MR revealed that genetic susceptibility to LC and its subtypes caused significant changes in three groups of GM.Conclusion: Our findings substantiate the causality between GM and LC and its subtypes. This study offers fresh insights into the function of GM in mediating the progression of LC.
- Top Cited PapersOpen Access
- 8 December 2022
- Published by Wiley in Thoracic Cancer
- Vol. 14 (1) , 3-11
Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040
Esophageal cancer is a familiar malignancy with high incidence and mortality, and the overall prognosis is poor. The numbers of cases of and deaths from esophageal cancer have risen rapidly in recent decades. It is one of the most malignant cancers, with more than 0.6 million new cases and 0.54 million deaths worldwide in 2020. Here, we present the global epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040 at different geographical levels of continents, regions and countries, and analyze them by gender, race, geographic region and human development index. We summarize the prospects for the esophageal cancer burden and risk factors in different areas, which will be useful for global esophageal cancer clinical therapy and cancer control planning.
- 8 December 2022
- Published by Wiley in Thoracic Cancer
- Vol. 14 (1) , 3-11
Top Cited PapersOpen AccessEpidemiology of esophageal cancer in 2020 and projections to 2030 and 2040
Esophageal cancer is a familiar malignancy with high incidence and mortality, and the overall prognosis is poor. The numbers of cases of and deaths from esophageal cancer have risen rapidly in recent decades. It is one of the most malignant cancers, with more than 0.6 million new cases and 0.54 million deaths worldwide in 2020. Here, we present the global epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040 at different geographical levels of continents, regions and countries, and analyze them by gender, race, geographic region and human development index. We summarize the prospects for the esophageal cancer burden and risk factors in different areas, which will be useful for global esophageal cancer clinical therapy and cancer control planning.